Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ERCC5
REST API REST API
Homo sapiens
ERCC5 is differentially expressed in 244 experiments: 106 organism parts: liver, lung, ... (104 more);, 141 disease states: normal, acute myeloid leukemia, ... (139 more);, 77 cell types 314 cell lines 35 compound treatments and 62 other conditions.
Synonyms ERCM2, XPGC
Orthologs Ercc5 (Mus musculus)   ercc5 (Danio rerio)   ERCC5 (Gallus gallus)   Q3B7N6_BOVIN (Bos taurus)   Ercc5 (Rattus norvegicus)   RAD2 (Saccharomyces cerevisiae)   mus201 (Drosophila melanogaster)   ercc5 (Xenopus laevis)   ERCC5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, DNA binding, nucleotide-excision repair, protein binding, DNA repair, double-stranded DNA binding, nuclease activity, negative regulation of apoptosis, protein N-terminus binding, metal ion binding, single-stranded DNA binding, determination of adult lifespan, multicellular organism growth, nucleus, endodeoxyribonuclease activity, protein homodimerization activity, endonuclease activity, nucleoplasm, catalytic activity, transcription-coupled nucleotide-excision repair, DNA-directed RNA polymerase II, holoenzyme, holo TFIIH complex, response to UV-C, UV protection, bubble DNA binding, nucleotide-excision repair, DNA incision, 3'-to lesion, nucleotide-excision repair, DNA damage removal
InterPro Term XPG_DNA_repair_N, XPG/RAD2_endonuclease, XPGC_DNA_repair, XPGC_Rad_DNA_repair, HhH2
UniProt Accession Q86UB2, Q9HD60, P28715, F2Z2A1, F8WDY3
Gene-Disease Assocation CEREBROOCULOFACIOSKELETAL SYNDROME 1; COFS1, XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP G; XPG
Search EB-eye ENSG00000134899
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (33 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF-7
2
E-GEOD-20081, E-GEOD-5823
SW480
2
E-MEXP-1014, E-GEOD-18005
MDA-MB-231
1
2
E-GEOD-5823, E-TABM-420, E-MTAB-62
NA19119
1
E-GEOD-19480
308 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-13909, E-GEOD-20677, ... (38 experiments)

Factor Value U/D Experiments
CD8+ T cell
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
1
E-AFMX-5
bronchial epithelial cell
1
E-TABM-145
mononuclear cell
1
E-GEOD-6053
basophil
1
E-GEOD-3982
BDCA1+ dendritic cell
1
E-TABM-34
71 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2508, E-GEOD-15960, E-GEOD-2466, ... (46 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-3726
Huntington's disease
2
E-GEOD-3790, E-AFMX-6
glioblastoma
2
E-GEOD-4290, E-MTAB-62
prostate carcinoma
2
E-MEXP-2034, E-MTAB-62
hiv; hiv infection; disease; conclusion; infection; disease progression
1
E-MTAB-62
plasma-cell leukemia
1
E-MTAB-62
135 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (29 experiments)

Factor Value U/D Experiments
none
5
7
E-GEOD-20719, E-GEOD-412, E-GEOD-5824, E-TABM-868, E-GEOD-2649, ... (12 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
baseline propofol
1
E-GEOD-4386
bacterial endotoxin
1
E-GEOD-3284
granulocyte-colony stimulating factor
1
E-GEOD-7400
hydroxyurea
1
E-GEOD-6431
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-2191, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138 ... (5 experiments)

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-22593, E-TABM-321, E-TABM-43, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-MEXP-1446, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-22309, E-GEOD-21750

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-4922

Processing time: 0.396 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM